lanthanum carbonate (Fosrenol)

06/01/2011 - "Lanthanum carbonate (LC) is a nonaluminum, noncalcium phosphate binder that is effective for hyperphosphatemia in dialysis patients. "
01/01/2005 - "Lanthanum carbonate, a new noncalcium, nonaluminum phosphate binder, represents a promising treatment for hyperphosphatemia."
07/01/2009 - "Although data on the safety and efficacy of lanthanum carbonate in the treatment of hyperphosphatemia have been provided in long-term clinical studies, there is still an ongoing scientific debate about its possible long-term toxicity. "
04/01/2013 - "Long-term efficacy of lanthanum carbonate on hyperphosphatemia was examined in multicenter dialysis patients. "
11/01/2008 - "The efficacy of lanthanum carbonate as a phosphate binder for the treatment of hyperphosphatemia has been reported, but not from a double-blind, comparator-controlled comparative study. "

01/01/2003 - "Lanthanum carbonate has shown significant promise in clinical trials in ESRD patients. "
06/01/2005 - "We report data from a recent trial, which, for the first time, assessed the efficacy and tolerability of lanthanum carbonate treatment, compared with placebo, in Chinese patients with ESRD. "
07/01/2004 - "A 4-week, open-label, dose-titration trial was conducted to assess the ability of lanthanum carbonate to control phosphate levels in patients with chronic renal failure. "
07/01/2004 - "Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate."
06/01/2011 - "Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure."

04/01/2013 - "Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease."
06/01/2011 - "Bone histomorphometry revealed a severe form of bone disease with fibrosis in CRF + vehicle animals; lanthanum carbonate treatment reduced the severity of the bone abnormalities observed, particularly woven bone formation and fibrosis. "
03/01/2004 - "Patients treated with lanthanum carbonate for 1 year did not experience any of the aluminium-like toxic effects on bone expressed as either osteomalacia or adynamic bone disease."
02/01/2005 - "This study provides an approach to the prospective evaluation of bone disease progression with therapy, and its application supports the safety and greater efficacy of one-year lanthanum carbonate versus calcium carbonate therapy as a means to normalize bone turnover in dialysis patients."
02/01/2005 - "Lanthanum carbonate moderated extreme forms of renal osteodystrophy, whereas calcium carbonate treatment increased the incidence of adynamic and predominant hyperparathyroid bone disease. "

11/01/2008 - "However, lanthanum carbonate is superior in terms of lowering the incidence of hypercalcemia."
02/01/2006 - "Lanthanum carbonate is an effective phosphate-binding agent without significant risk of hypercalcemia or worsening metabolic acidosis. "
01/01/2005 - "This 6-month study demonstrates that serum phosphate control with lanthanum carbonate (750-3,000 mg/day) is similar to that seen with calcium carbonate (1,500-9,000 mg/day), but with a significantly reduced incidence of hypercalcemia. "
02/01/2009 - "In clinical studies (La2[CO3]3) has a similar ability to calcium carbonate in controlling serum phosphate level without hypercalcemia. "
09/01/2007 - "Lanthanum carbonate has similar phosphate control to calcium-based binders with less incidence of hypercalcemia but long-term clinical studies are needed for testing long-term exposure. "

02/01/2009 - "[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate]."
12/01/2015 - "Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis."
03/01/2015 - "Lanthanum carbonate could delay the progression of vascular calcification and benefit chronic kidney disease patients on bone outcomes. "
01/01/2013 - "Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review."
08/01/2011 - "Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients."